Belite Bio (STU:D01) Pretax Margin %: % (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:D01 Belite Bio Inc STU:D01
20 GF Score
Price €131.00
! 3 Warning Signs
View Full Analysis

What is Belite Bio Pretax Margin %?

Belite Bio STU:D01 +1.55% 20 Pretax Margin % is % as of Mar. 2026. GuruFocus rates STU:D01 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 941 Biotechnology companies, Belite Bio ranks worse than 106269.82% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Belite Bio's Pre-Tax Income for the three months ended in Mar. 2026 was €-23.30 Mil. Belite Bio's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Belite Bio's pretax margin for the quarter that ended in Mar. 2026 was %.

The historical rank and industry rank for Belite Bio's Pretax Margin % or its related term are showing as below:


STU:D01's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.42
* Ranked among companies with meaningful Pretax Margin % only.

Belite Bio  (STU:D01) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Belite Bio Pretax Margin % Related Terms

Belite Bio Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Belite Bio's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Belite Bio Pretax Margin % Chart

Belite Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Pretax Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Belite Bio Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:D01 vs DFTX, LGND, XENE: Pretax Margin % Comparison

For the Biotechnology subindustry, Belite Bio's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Belite Bio Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Belite Bio's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Belite Bio's Pretax Margin % falls into.


STU:D01
20GF Score
Belite Bio Inc STU:D01
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Belite Bio Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Belite Bio's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-66.28/0
= %

Belite Bio's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-23.301/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of % mean?
Belite Bio (STU:D01) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Belite Bio and its competitors. According to the industry distribution chart, Belite Bio ranks #999999 out of 941 companies in the Biotechnology industry.
Is Belite Bio's Pretax Margin % too high?
Belite Bio's current Pretax Margin % is %. Based on the distribution chart, Belite Bio ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Belite Bio has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Belite Bio's Pretax Margin % compare to DFTX and LGND?
According to the Biotechnology industry distribution chart, Belite Bio ranks #999999 out of 941 companies for Pretax Margin %. This places Belite Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Belite Bio and its competitors. Belite Bio's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belite Bio stock overvalued right now?
Belite Bio (STU:D01) has a current Pretax Margin % of %. The current Pretax Margin % is %. Belite Bio's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Belite Bio (STU:D01), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Belite Bio Business Description

Other Exchanges BLTE:USA
Address 12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
20GF Score

Get the complete analysis for STU:D01

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€131.00
Price